ArticleWorld journal of surgical oncology2025
HROB is a novel prognostic biomarker correlated with immune cell infiltration and tumor progression in lung adenocarcinoma.
Article in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- BUB1B is a novel prognostic-related biomarker and correlated with immune infiltrates in lung adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- A comprehensive study integrating bioinformatics analysis and experimental results on HROB as a potential biomarker for the prognosis of lung adenocarcinoma.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) is characterized by poor prognosis and limited treatment options. The homologous recombination factor with OB-fold (HROB) is reportedly associated with DNA repair, playing an essential role in a variety of cancers. However, the functional impact, clinical relevance, and underlying mechanisms of HROB in LUAD remain elusive, prompting this study to comprehensively characterize its expression profile and pathogenetic contributions.
methodsWe first systematically profiled HROB expression across pan-cancer contexts and multiple cell lines. To characterize its clinical relevance in LUAD, we employed receiver operator characteristic (ROC) curves, Kaplan-Meier survival analyses, and univariate and multivariate Cox regression modeling. Potential molecular mechanisms underlying HROB function were interrogated enrichment analyses and immune correlation studies. Using RT-PCR, we quantified HROB expression in different LUAD cell lines, followed by functional characterization through Cell Counting Kit-8(CCK-8), 5-Ethynyl-2'-deoxyuridine (EdU), wound-healing, and Transwell assays.
resultsHROB exhibited significant overexpression in LUAD tissues compared to normal, with high diagnostic accuracy. Elevated HROB expression was strongly associated with adverse clinical outcomes. Bioinformatics analysis revealed HROB's involvement in modulating immune cell infiltration, regulating cell cycle progression and DNA repair pathways. Besides, BUB1B, BUB1, NUF2, CCNB2, CCNB1, KIF11, KIF2C, TPX2, DLGAP5, and CDCA8 were identified as potential hub genes within HROB-associated signaling modules. Knocking down HROB expression inhibited LUAD cell proliferation, migration, and invasion.
conclusionsHROB is upregulated in LUAD and represents a promising prognostic biomarker, driving tumor proliferation, migration, and invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.